title: Rituximab and chlorambucil versus rituximab alone in gastric mucosa-associated lymphoid tissue lymphoma according to t(11;18) status: a monocentric non-randomized observational study.
abstract: Forty-nine patients, t(11;18)-positive (n = 31) and t(11;18)-negative (n = 18), were treated without randomization with rituximab-chlorambucil or rituximab alone. Evaluation was performed at week (W) 6, week (W) 25 and every 6 months (Wx). Comparing the rituximab-chlorambucil group to the rituximab-alone group, remission was obtained in 93% vs. 66% at W6 (p = 0.01), in 93% vs. 81% at W25 (p = 0.14) and in 93% vs. 76% at Wx (p = 0.07). Comparing the rituximab-chlorambucil group to the rituximab-alone group in t(11;18)-positive patients, remission was obtained in 100% vs. 45% at W6 (p = 0.0005), in 100% vs. 66% at W25 (p = 0.01) and in 96% vs. 55% at Wx (p = 0.01). Comparing the rituximab-chlorambucil group to the rituximab-alone group in t(11;18)-negative patients, remission was obtained in 66% vs. 83% at W6 (p = 0.32), in 66% vs. 92% at W25 (p = 0.22) and in 83% vs. 92% at Wx (p = 0.47). In conclusion, rituximab-chlorambucil is significantly more rapidly efficient than rituximab alone. In t(11;18)-positive patients, the combination is more efficient than rituximab alone. In t(11;18)-negative patients, rituximab alone is as efficient as rituximab-chlorambucil and may be an alternative treatment.
authors.affiliation: Service d'Hépatologie et de Gastroentérologie, APHP, Groupe hospitalier Henri Mondor-Albert Chenevier, Créteil, France. michalevy@free.fr
authors.forename: Michaël
authors.initials: M
authors.lastname: Lévy
authors.forename: Christiane
authors.initials: C
authors.lastname: Copie-Bergman
authors.forename: Aurélien
authors.initials: A
authors.lastname: Amiot
authors.forename: Jehan
authors.initials: J
authors.lastname: Dupuis
authors.forename: Yann
authors.initials: Y
authors.lastname: Le Baleur
authors.forename: Karim
authors.initials: K
authors.lastname: Belhadj
authors.forename: François
authors.initials: F
authors.lastname: Hémery
authors.forename: Iradj
authors.initials: I
authors.lastname: Sobhani
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Delfau-Larue
authors.forename: Karen
authors.initials: K
authors.lastname: Leroy
authors.forename: Corinne
authors.initials: C
authors.lastname: Haioun
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Delchier
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002699:Chlorambucil / Q000008:administration & dosage; D002880:Chromosomes, Human, Pair 11; D002887:Chromosomes, Human, Pair 18; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D000069283:Rituximab; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D014178:Translocation, Genetic; D016896:Treatment Outcome
chemical_list: C415943:API2-MALT1 fusion protein, human; D058846:Antibodies, Monoclonal, Murine-Derived; D015514:Oncogene Proteins, Fusion; D002699:Chlorambucil; D000069283:Rituximab